285 related articles for article (PubMed ID: 20885015)
1. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran.
Azarpira N; Namazi S; Hendijani F; Banan M; Darai M
Pharmacol Rep; 2010; 62(4):740-6. PubMed ID: 20885015
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
Zand N; Tajik N; Moghaddam AS; Milanian I
Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
[TBL] [Abstract][Full Text] [Related]
3. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
4. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
5. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
[TBL] [Abstract][Full Text] [Related]
6. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population.
Efrati E; Elkin H; Sprecher E; Krivoy N
Curr Drug Saf; 2010 Jul; 5(3):190-3. PubMed ID: 20210733
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population.
Djaffar-Jureidini I; Chamseddine N; Keleshian S; Naoufal R; Zahed L; Hakime N
Genet Test Mol Biomarkers; 2011 Nov; 15(11):827-30. PubMed ID: 21651319
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.
Bravo-Villalta HV; Yamamoto K; Nakamura K; Bayá A; Okada Y; Horiuchi R
Eur J Clin Pharmacol; 2005 May; 61(3):179-84. PubMed ID: 15776277
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.
Jose R; Chandrasekaran A; Sam SS; Gerard N; Chanolean S; Abraham BK; Satyanarayanamoorthy K; Peter A; Rajagopal K
Fundam Clin Pharmacol; 2005 Feb; 19(1):101-5. PubMed ID: 15660966
[TBL] [Abstract][Full Text] [Related]
10. Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians.
Nahar R; Deb R; Saxena R; Puri RD; Verma IC
Pharmacol Rep; 2013; 65(1):187-94. PubMed ID: 23563037
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population.
Hadjipanagi D; Chrysanthou S; Voskarides K; Deltas C
BMC Res Notes; 2014 Mar; 7():123. PubMed ID: 24593903
[TBL] [Abstract][Full Text] [Related]
12. Frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population.
Rathore SS; Agarwal SK; Pande S; Mittal T; Mittal B
Biosci Trends; 2010 Dec; 4(6):333-7. PubMed ID: 21248432
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
14. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
[TBL] [Abstract][Full Text] [Related]
15. Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia.
Alzahrani AM; Ragia G; Hanieh H; Manolopoulos VG
Biomed Res Int; 2013; 2013():315980. PubMed ID: 23586031
[TBL] [Abstract][Full Text] [Related]
16. Allele and genotype frequencies of CYP2C9 within an Iranian population (Mazandaran).
Hashemi-Soteh SM; Shahabi-Majd N; Gholizadeh AR; Shiran MR
Genet Test Mol Biomarkers; 2012 Jul; 16(7):817-21. PubMed ID: 22288731
[TBL] [Abstract][Full Text] [Related]
17. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
[TBL] [Abstract][Full Text] [Related]
18. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai, Tibetan Chinese.
Zeng WT; Zheng QS; Huang M; Cen HJ; Lai Y; Chen WY; Zhao LZ; Leng XY
Pharmazie; 2012 Jan; 67(1):69-73. PubMed ID: 22393834
[TBL] [Abstract][Full Text] [Related]
20. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
Scott SA; Edelmann L; Kornreich R; Desnick RJ
Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
